Confo Therapeutics’ technology stabilizes functional conformations of G protein-coupled receptors to uncover a wide range of previously inaccessible drug targets
Confo Therapeutics, a spin-off of the Vrije Universiteit Brussel and VIB, is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. Confo Therapeutics employs its proprietary CONFO technology to lock inherent unstable functional conformations of GPCRs as a superior starting point for drug discovery. CONFO body-stabilized active state conformations of these receptors disclose previously inaccessible structural features empowering the discovery of novel agonists for better therapeutic intervention.
Spica Therapeutics is pioneering Macrophage-Subset targeted therapies
VoxelSensors is developing ultra-low power and ultra-low latency 3D perception sensors for Extended Reality
THERAtRAME develops and positions new therapeutics targeting tRNA epitranscriptomics in cancer
